Skip to main content
Explore URMC
menu

Chunkit Fung, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Administrative: (585) 275-0394

Office: (585) 275-5823

Fax: (585) 273-1042

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting

Cancer

Biography

I chose this specialty because of the many exciting new therapeutic options for patients with genitourinary cancers, as well as the opportunity to become an integral part of a team that cares for patients during one of their most difficult times.

As my patient, you can depend on me for compassion and dedication, in addition to an innovative and patient-centered approach to care. My research interests are clinical trials for genitourinary cancers and cancer survivorship research. During my free time, I enjoy running, hiking, cooking and travel.

Conditions I Treat

- Prostate cancer
- Bladder cancer
- Testicular cancer
- Kidney cancer
- Adrenal cancer

Professional Background

Dr. Chunkit Fung graduated Summa Cum Laude with Distinction in Research from Cornell University in 2000. He then went on to Medical School at the University of Pennsylvania in Philadelphia, PA and graduated with his M.D in 2004. He completed his internal medicine Internship and Residency from 2004 through 2007 at the Hospital of the University of Pennsylvania. He held the position of Instructor in the Department of Medicine from the University of Pennsylvania from 2007 to 2008 and subsequently completed his Fellowship in Hematology and Oncology at the Hospital of the University of Pennsylvania from 2008 to 2011. He also received a Master in Clinical Epidemiology in 2012 from the University of Pennsylvania School in Medicine. In July 2011, he came to the University of Rochester School of Medicine and Dentistry as an Assistant Professor in the Department of Hematology and Oncology. His clinical research interests are developing clinical trials to evaluate new therapies in Genitourinary Oncology and Cancer Survivorship Research.

Research

I am a medical oncologist specialized in genitourinary malignancy and an Assistant Professor of medicine with research interests in cancer control, particularly in the development, implementation, and dissemination of mHealth behavioral interventions to prevent and manage treatment- and cancer-related toxicities in cancer survivors, with a specific focus in cardiovascular complications from cancer treatment. Additionally, I am interested in developing clinical trials to evaluate new therapeutics for treatment of urologic malignancies.

Credentials

Specialties

  • Internal Medicine
  • Medical Oncology - American Board of Internal Medicine

Education

2004
MD | University of Pennsylvania School of Medicine

Post-doctoral Training & Residency

07/01/2008 - 06/01/2011
Fellowship in Hematology/Oncology at Hospital of the University of Pennsylvania

07/01/2005 - 06/30/2007
Residency in Internal Medicine at Hospital of the University of Pennsylvania

07/01/2005 - 06/01/2007
Internship in Internal Medicine at Hospital of the University of Pennsylvania

VIEW ALL expand_more

Awards

2020
Human Rights Campaign Leadership Award for Rising Star Gala Leaders

2019
Presidential Diversity Award Nominee, University of Rochester

2018 - 2018
Civic Leadership Award
Sponsor: US TOO Prostate Cancer Support Group
Location: Rochester, NY

2018
URMC Wilmot Cancer Institute, Hematology/Oncology Fellowship Training Program, Teacher of the Year 2017/2018

2016 - 2018
Empire Clinical Research Investigator Program Fellowship Grant

2016
Strong Star Certificate of Appreciation

2015
Strong Star Certificate of Appreciation

2014
Strong Star Certificate of Appreciation

2013
Strong Star Certificate of Appreciation

2012 - 2015
Wimot Cancer Center Research Fellowship
Sponsor: Wimot Cancer Center

2012
Strong Star Certificate of Appreciation

2012
Patient and Family Centered Care Award

2011
American Society of Clinical Oncology Trainee Travel Award
Sponsor: American Society of Clinical Oncology

2010
National Institute of Health Loan Repayment Program
Sponsor: National Institute of Health

2000
Summa Cum Laude with Distinction in Research
Sponsor: Cornell University

1999
Howard Hughes Medical Institute Undergraduate Research Scholarship
Sponsor: Howard Hughes Medical Institute

VIEW ALL expand_more

Clinical Trials

A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors

Lead Researcher: Chunkit Fung

This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. Studying samples of blood from patients with germ cell cancers in the laboratory may help doctors predict how likely the cancer will come back.

View Study Details

A Study of Enfortumab Vedotin (ASG-22CE) as Monotherapy or in Combination With Other Anticancer Therapies for the Treatment of Urothelial Cancer

Lead Researcher: Chunkit Fung

This study will test an experimental drug (enfortumab vedotin) alone and with different combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI) that is used to treat patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra. Some parts of the study will look at locally-advanced and metastatic urothelial cancer, which means the cancer has spread to nearby tissues or to other areas of the body. Other parts of the study will look at muscle-invasive bladder cancer (MIBC), which is cancer at an earlier stage that has spread into the muscle wall of the bladder. This study will look at the side effects of enfortumab vedotin alone and with other anticancer therapies. A side effect is a response to a drug that is not part of the treatment effect. This study will also test if the cancer shrinks with the different treatment combinations.

View Study Details

UGUK17036: Monitoring of Treatment Related Toxicities from Oral Targeted Agents and Immunotherapy Among Patients with Advanced Renal Cell Carcinoma (RCC) Using Carevive Software, a Single-Arm Phase II Feasibility Study.

Lead Researcher: Chunkit Fung

To determine if Carevive software, which monitors treatment-related toxicities and then generates self-care management plans for these symptoms, will be feasible to implement among patients with metastatic renal cell carcinoma (RCC). Additionally for collection of preliminary data on treatment-related toxicities, quality of life, distress level, and drug adherence.

View Study Details

A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer (NIAGARA)

Lead Researcher: Chunkit Fung

A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer

View Study Details

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Lead Researcher: Chunkit Fung

This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading.

View Study Details

DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).,DORA Trial: Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Lead Researcher: Chunkit Fung

The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone.

View Study Details

Publications

Journal Articles

9/30/2020
Trendowski MR, Wheeler HE, El Charif O, Feldman DR, Hamilton R, Vaughn DJ, Fung C, Kollmannsberger C, Einhorn LH, Travis LB, Dolan ME. "Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors." Clinical cancer research : an official journal of the American Association for Cancer Research.. 2020 Sep 30; Epub 2020 Sep 30.

8/2020
Kerns SL, Fung C, Fossa SD, Dinh PC, Monahan P, Sesso HD, Frisina RD, Feldman DR, Hamilton RJ, Vaughn D, Martin N, Huddart R, Kollmannsberger C, Sahasrabudhe D, Ardeshir-Rouhani-Fard S, Einhorn L, Travis LB. "Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors." . 2020 Aug 0; 4(4):pkaa022. Epub 2020 Mar 20.

6/2020
Milano MT, Dinh PC, Yang H, Zaid MA, Fossa SD, Feldman DR, Monahan PO, Travis LB, Fung C. "Solid and Hematologic Neoplasms After Testicular Cancer: A US Population-Based Study of 24?900 Survivors." . 2020 Jun 0; 4(3):pkaa017. Epub 2020 Mar 17.

Books & Chapters

2017
Chapter Title: Second Cancers
Book Title: Cancer: Principles & Practice of Oncology, 11th Edition
Author List: Fung, C., Bhatia, S., Allan, J.M., Oeffinger, K.C., Ng, A., Travis L.B.
Edited By: DeVita, V.T. Jr., Lawrence, TS., Rosenberg, S.A.
Published By: Wolters Kluwer Health 2017 in Philadelphia

2014
Chapter Title: Second Malignant Neoplasms and Cardiovascular Disease Among Testicular Cancer Survivors
Book Title: Testicular Cancer: Diagnosis and Clinical Management
Author List: Fung, C., Fossa SD, Travis LB
Edited By: Einhorn LH, Horwich A, Huddart R
Published By: Oxford: Blackwell Publishing 2014

2014
Chapter Title: Second Malignant Neoplasms Among Testicular Cancer Survivors
Book Title: EAU-ICUD Consultation on Medical Treatment of Urological Malignancies
Author List: Fung, C., Travis, LB, Warde
Edited By: Massard C, Zhou FJ, Fossa SD
Published By: EAU-ICUD 2014

VIEW ALL PUBLICATIONS